Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
67 Ergebnisse für "revenues" unter Somagenetix
Vogel, Hans-Ulrich: Marco Polo Was in China. New evidence from curr...
... , salts and revenues. Asiatische Studien / Études Asiatiques, 69(3):787-793. Copy 44 downloads since 12 ... Vogel, Hans-Ulrich: Marco Polo Was in China. New evidence from currencies, salts and revenues ... Vogel, Hans-Ulrich: Marco Polo Was in China. New evidence from currencies, salts and revenues ... Vogel, Hans-Ulrich: Marco Polo Was in China. New evidence from currencies, salts and revenues ...
Piracy and box office movie revenues: Evidence from Megaupload - Zu...
... revenues: Evidence from Megaupload. International Journal of Industrial Organization, 52:188-215. Copy ... on box office revenues of wide-release vs. niche movies. Identification comes from a comparison of ... Piracy and box office movie revenues: Evidence from Megaupload - Zurich Open Repository and Archive ... Piracy and box office movie revenues: Evidence from Megaupload - Zurich Open Repository and Archive ... Piracy and box office movie revenues: Evidence from Megaupload - Zurich Open Repository and Archive ...
Kuros Biosciences AG
8952 Schlieren, Wagistrasse 25
+41 (0)44 733 4747
Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing.
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
25 Ergebnisse für "revenues" unter Kuros Biosciences AG
Comments on: Kuros to receive $7 million up front and potentially $...
... Comments on: Kuros to receive $7 million up front and potentially $166.5 million in future revenues ... revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate ... Comments on: Kuros to receive $7 million up front and potentially $166.5 million in future revenues ... -future- revenues-under-a-royalty-purchase-agreement-with-xoma-related-to-kuross-license-agreement-with ... Comments on: Kuros to receive $7 million up front and potentially $166.5 million in future revenues ...
Kuros to receive $7 million up front and potentially $166.5 million...
... Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a ... -future- revenues-under-a-royalty-purchase-agreement-with-xoma-related-to-kuross-license-agreement-with ... Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
10 Ergebnisse für "revenues" unter Bio-Technopark Schlieren-Zürich
Kuros to receive $7 million up front and potentially $166.5 million...
... News Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a ... Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a ... -million-in-future- revenues-under-a-royalty-purchase-agreement-with-xoma-related-to-kuross-license ... Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a ...
Kuros Biosciences Reports Results for First Half 2019 › BIO-TECHNOP...
... maintenance and administration. Revenues amounted to CHF 0.9 million (first half 2018: CHF 0.3 million) and ... originated from product sales. Revenues in the first half of 2018 related to a payment from the agreement ... million) contained costs for personnel and other expenses for maintenance and administration. Revenues ... amounted to CHF 0.9 million (first half 2018: CHF 0.3 million) and originated from product sales. Revenues ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
54 Ergebnisse für "revenues" unter ETH Entrepreneurship
... Expenses 01 food 135.25 02 communication 74 03 transportation 17.50 total expenses 226.75 Revenues R1 ... salary 250 R2 interests 0.25 total revenues 250.25 Assets status 01-01-2021 1024.60 gain/loss 23.50 ... Expenses 01 food 135.25 02 communication 74 03 transportation 17.50 total expenses 226.75 Revenues R1 ... salary 250 R2 interests 0.25 total revenues 250.25 Assets status 01-01-2021 1024.60 gain/loss 23.50 ...
General Assembly and Fondue Night – VMI
... /16 Adoption of the statement of revenues and expenditures for the period 2015/16 Adoption of the ... revenues and expenditures for the period 2015/16 Adoption of the budget for the period 2016/17 Elections 8a ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
45 Ergebnisse für "revenues" unter University of Zurich
UZH - UZH Life Sciences Fund - Donate
... revenues flowing back from its investments (evergreen structure). Your donation is sustainable as it ... invested in spin-offs and the LSF will reinvest any revenues flowing back from its investments (evergreen ...
UZH - Department of Informatics - Communication Systems Group - New...
... day. In terms of activities as well as revenues TC6 is one of the largest TCs within IFIP, which ... afternoon, he re-appointed Burkhard that same day. In terms of activities as well as revenues TC6 is one of ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
6 Ergebnisse für "revenues" unter Molecular Partners AG
Molecular Partners 1H 2015 Release - Molecular Partners
... : In line with management expectations and guidance In 1H 2015, the company recognized total revenues ... million). CHF 7.6 million of total revenues was with Allergan, CHF 2.8 million with Roche and CHF 0.8 ... 2015 Key Financials (CHF million, except per share, FTE data) 1H 2015 1H 2014 change Total revenues ... recognized total revenues of CHF 11.2 million, 18% less than in the comparable period of the previous year ...
Molecular Partners reports its results for the Financial Year 2014 ...
... 2012 FY 2011 Total revenues -0.15 4.83 8.91 -0.46 92.3 -17.1 49.0 28.9 188.4 96.1 113.2 64.2 67.2 66.8 ... 18% lower revenues of CHF 26.6 million (2013: CHF 32.4 million), of which CHF 16.6 million with ... , FTE data) FY 2014 FY 2013 FY 2012 FY 2011 Total revenues 26.6 32.4 35.6 18.1 R&D expenses -19.8 ... , Molecular Partners recorded 18% lower revenues of CHF 26.6 million (2013: CHF 32.4 million), of which CHF ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Wagistrasse 25
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Wagistrasse 25
8952 Schlieren
5 Ergebnisse für "revenues" unter CSL Vifor
CSL Annual Report 2023 – Page 120
... measured based on the segment operating result, being the revenues and costs directly under the control of ... revenues and costs directly under the control of the business unit. The Group’s operating segments are: CSL ...
CSL Annual Report 2022 – Page 64
... revenues and profits derived outside Australia. We separately report on our global tax footprint, as part ... is a truly global company, with more than 90% of our revenues and profits derived outside Australia ...
Microcaps AG
8952 Schlieren, Wagistrasse 13
+41 44 733 45 50
alessandro.ofner@microcaps.ch
Making sure that drugs are released in the affected part of the body and at a specific rate is a huge challenge, because the size of the capsules that deliver these active ingredients is uncontrollable. At Microcaps we developed a patented technology that enables the size control of these microcapsules with Swiss precision, hence they all behave exactly the same. This means we can directly tailor and predict the release profile of a drug. Our solution is also highly relevant for fragrances, flavors and probiotics.
Microcaps AG
Wagistrasse 13
8952 Schlieren
1 Ergebnisse für "revenues" unter Microcaps AG
210118_PartnerMM Microcaps EN_InputZKB
... to this stage. We have already registered our first revenues from formulation development and are ... to this stage. We have already registered our first revenues from formulation development and are ...
Standortförderung Kanton Zürich
https://www.zh.ch/de/volkswirtschaftsdirektion/amt-fuer-wirtschaft/standortfoerderung.html
8090 Zürich, Walchestrasse 19
+41 43 259 49 92
standort@vd.zh.ch
The Division of Business and Economic Development supports resident companies, promotes Zurich's innovation capacity by way of connecting the relevant stakeholders in key industries, fosters external economic relations and offers guidance to companies interested in moving to Zurich.
Standortförderung Kanton Zürich
Walchestrasse 19
8090 Zürich
3 Ergebnisse für "revenues" unter Standortförderung Kanton Zürich
Ratingbericht Fitch 2019
... activities, with personal income tax (PIT) accounting for about 70% of the canton's tax revenues. The other ... two main sources of the canton's operating revenues are transfers (31% of operating revenue) and ... activities, with personal income tax (PIT) accounting for about 70% of the canton's tax revenues. The other ... two main sources of the canton's operating revenues are transfers (31% of operating revenue) and ...
Ratingbericht Fitch 2020
... main sources of the canton’s operating revenues are transfers (31% of operating revenue) and charges ... 7,721 Transfers received 4,450 4,332 4,591 4,742 4,665 4,735 Fees, fines and other operating revenues ... main sources of the canton’s operating revenues are transfers (31% of operating revenue) and charges ... 7,721 Transfers received 4,450 4,332 4,591 4,742 4,665 4,735 Fees, fines and other operating revenues ...
InSphero AG
8952 Schlieren, Wagistrasse 27
+41 44 515049-0
info@insphero.com
InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.
InSphero AG
Wagistrasse 27
8952 Schlieren
